Pluri (PLUR) Cash & Current Investments (2010 - 2025)
Pluri (PLUR) posted quarterly Cash & Current Investments of $4.9 million for Q4 2025, down 34.39% year-over-year from $7.5 million in Q4 2024, and up 4.84% quarter-over-quarter from $4.7 million in Q3 2025.
Pluri (PLUR) Cash & Current Investments (2010 - 2025) Analysis & Trends
Pluri (PLUR) has reported Cash & Current Investments for 16 consecutive years, with $4.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash & Current Investments fell 34.39% year-over-year to $4.9 million; the TTM figure through Dec 2025 stood at $4.9 million (down 34.39% YoY), while the FY2025 annual figure was $20.6 million, down 31.26% from the prior year.
- Cash & Current Investments grew to $4.9 million in Q4 2025 per PLUR's latest filing, from $4.7 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $65.5 million in Q2 2021 and bottomed at $906000.0 in Q1 2023.
- Historically, Cash & Current Investments has averaged $25.5 million across 5 years, with a median of $20.2 million in 2021.
- Annual changes were most pronounced in 2023 — Cash & Current Investments plunged 97.06% — and 2024, when it surged 812.14%.
- Pluri's Cash & Current Investments stood at $19.7 million in 2021, then soared by 139.47% to $47.2 million in 2022, then slumped by 97.06% to $1.4 million in 2023, then surged by 438.46% to $7.5 million in 2024, then sank by 34.39% to $4.9 million in 2025.
- Business Quant data shows PLUR's Cash & Current Investments at $4.9 million in Q4 2025, $4.7 million in Q3 2025, and $20.6 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | 12.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.91 Mn |
| Sep 30, 2025 | 4.69 Mn |
| Jun 30, 2025 | 20.61 Mn |
| Mar 31, 2025 | 8.91 Mn |
| Dec 31, 2024 | 7.49 Mn |
| Sep 30, 2024 | 3.56 Mn |
| Jun 30, 2024 | 29.99 Mn |
| Mar 31, 2024 | 8.26 Mn |
| Dec 31, 2023 | 1.39 Mn |
| Sep 30, 2023 | 5.55 Mn |
| Jun 30, 2023 | 41.07 Mn |
| Mar 31, 2023 | 906,000.00 |
| Dec 31, 2022 | 47.25 Mn |
| Sep 30, 2022 | 49.30 Mn |
| Jun 30, 2022 | 56.66 Mn |
| Mar 31, 2022 | 25.40 Mn |
| Dec 31, 2021 | 19.73 Mn |
| Sep 30, 2021 | 61.28 Mn |
| Jun 30, 2021 | 65.55 Mn |
| Mar 31, 2021 | 47.37 Mn |